
Reports Q3 revenue $6.4M vs. $6.8M last year. Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “During the third quarter of 2026, we took decisive steps to reduce costs
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| VVOS | Vivos Therapeutics | 0.08 | -2.19 | -96.65% |
| Name | Price | % Change | |
|---|---|---|---|
| $0.08 | -96.65% |

Reports Q3 revenue $6.4M vs. $6.8M last year. Kirk Huntsman, Vivos’ Chairman and Chief Executive Officer, stated, “During the third quarter of 2026, we took decisive steps to reduce costs

Vivos Therapeutics, Inc. (VVOS) is scheduled to report 3rd quarter earnings on 11/18/2026. Regarding Q3 estimates, Wall Street analysts expect Vivos Therapeutics, Inc. to post earnings of -$0.30 per share.

Vivos Therapeutics (VVOS) announced receipt of a letter from the Listing Qualifications staff of Nasdaq on October 20 stating that the company currently complies with Listing Rule 5550(b)(1), requiring the

Vivos Therapeutics ( ($VVOS) ) has provided an announcement. On October 20, 2026, Vivos Therapeutics received confirmation from Nasdaq that it had regained compliance with the Capital Market’s shareholders’ equity

Vivos Therapeutics ( ($VVOS) ) has provided an announcement. On October 16, 2026, Vivos Therapeutics closed a stock‑for‑asset transaction with precision‑health firm SOD Sciences, acquiring an 11% fully diluted equity

Vivos Therapeutics ( ($VVOS) ) has provided an announcement. On October 14, 2026, Vivos Therapeutics agreed to issue $12 million in newly created Series C Convertible Preferred Stock to SOD

Vivos Therapeutics (VVOS) announced that it has entered into a definitive mutual stock purchase and asset exchange agreement to acquire an 11% fully diluted equity interest in SOD Sciences and

Vivos Therapeutics (VVOS) announced execution by management on a restructuring and cost reduction plan aimed at saving an estimated $3.6M annually, beginning in Q4 2026. Parts of the plan have

Vivos Therapeutics (VVOS) announced the execution of definitive collaboration and operating agreements with South Palm Cardiovascular Associates, or SPCVA, to support the establishment and operation of a regional Sleep &

Vivos Therapeutics, Inc. (($VVOS)) has held its Q2 earnings call. Read on for the main highlights of the call. Vivos Therapeutics’ latest earnings call painted a mixed picture for investors.
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $2.70M | $-0.20 | $6.02M | 0.14 | -0.05 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.